Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, March 4, 2024
[ Mon, Mar 04th 2024
] - WOPRAI
[ Mon, Mar 04th 2024
] - WOPRAI
[ Mon, Mar 04th 2024
] - WOPRAI
[ Mon, Mar 04th 2024
] - WOPRAI
[ Mon, Mar 04th 2024
] - WOPRAI
[ Mon, Mar 04th 2024
] - WOPRAI
[ Mon, Mar 04th 2024
] - WOPRAI
[ Mon, Mar 04th 2024
] - WOPRAI
[ Mon, Mar 04th 2024
] - WOPRAI
[ Mon, Mar 04th 2024
] - WOPRAI
[ Mon, Mar 04th 2024
] - WOPRAI
[ Mon, Mar 04th 2024
] - WOPRAI
[ Mon, Mar 04th 2024
] - WOPRAI
[ Mon, Mar 04th 2024
] - WOPRAI
[ Mon, Mar 04th 2024
] - WOPRAI
[ Mon, Mar 04th 2024
] - WOPRAI
[ Mon, Mar 04th 2024
] - WOPRAI
[ Mon, Mar 04th 2024
] - WOPRAI
[ Mon, Mar 04th 2024
] - WOPRAI
[ Mon, Mar 04th 2024
] - WOPRAI
[ Mon, Mar 04th 2024
] - WOPRAI
[ Mon, Mar 04th 2024
] - WOPRAI
[ Mon, Mar 04th 2024
] - WOPRAI
[ Mon, Mar 04th 2024
] - WOPRAI
[ Mon, Mar 04th 2024
] - WOPRAI
[ Mon, Mar 04th 2024
] - WOPRAI
[ Mon, Mar 04th 2024
] - WOPRAI
[ Mon, Mar 04th 2024
] - WOPRAI
Bill Maughan Maintained (YMAB) at Strong Buy with Increased Target to $26 on, Mar 4th, 2024
Bill Maughan of Canaccord Genuity, Maintained "Y-mAbs Therapeutics, Inc." (YMAB) at Strong Buy with Increased Target from $22 to $26 on, Mar 4th, 2024.
Bill has made no other calls on YMAB in the last 4 months.
There is 1 other peer that has a rating on YMAB. Out of the 1 peers that are also analyzing YMAB, 0 agree with Bill's Rating of Hold.
This is the rating of the analyst that currently disagrees with Bill
- Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $21 on, Tuesday, February 20th, 2024
